SEARCH

SEARCH BY CITATION

Reference

  • 1
    Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999; 80: 827841.
  • 2
    Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 major cancers in 1990. Int J Cancer 1999; 83: 1829.
  • 3
    London WT, McGlynn KA. Liver Cancer. In: SchottenfeldD, FraumeniJF, Jr., eds. Cancer Epidemiology and Prevention. New York: Oxford University Press, 1996; 772793.
  • 4
    Robinson WS, Miller RH, Klote L, Marion PL, Lee SC. Hepatitis B virus and hepatocellular carcinoma. In: VyasGN, DienstagJL, HoofnagleJH, eds. Viral Hepatitis and Liver Disease. New York, NY: Grune and Stratton, Inc.; 1984: 245263.
  • 5
    Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991; 350: 427428.
  • 6
    Bressac B, Kew M, Wands J, Oxturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350: 429431.
  • 7
    McGlynn KA, Rosvold EA, Lustbader ED, Hu Y, Clapper ML, Zhou T, Wild CP, et al. Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. Proc Natl Acad Sci U S A 1995; 92: 23842387.
  • 8
    Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, et al. Genetic alternations during colorectal tumor development. N Engl J Med 1988; 319: 525532.
  • 9
    Baek MJ, Piao Z, Kim N-G, Park C, Shin E-C, Park J-H, Jung H-J, et al. p16 is a major inactivation target in hepatocellular carcinoma. Cancer 2000; 89: 6068.
  • 10
    Fang W, Piao Z, Simon D, Shue J-C, Huang S. Mapping of a minimal deleted region in human hepatocellular carcinoma to 1p36.13-p36.23 and mutational analysis of the RIZ (PRDM2) gene localized to the region. Genes Chromosomes Cancer 2000; 28: 269275.
  • 11
    Kanai Y, Ushijima S, Tsuda H, Sakamoto M, Hirohashi S. Aberrant DNA methylation precedes loss of heterozygosity on chromosome 16 in chronic hepatitis and liver cirrhosis. Cancer Lett 2000; 148: 7380.
  • 12
    Piao Z, Park C, Lee JS, Yang CH, Choi KY, Kim H. Homozygous deletions of the CKDN2 gene and loss of heterozygosity in primary hepatocellular carcinoma. Cancer Lett 1998; 122: 201207.
  • 13
    Buetow KH, Murray JC, Israel JL, London WT, Smith M, Kew M, Blanquet V, et al. Loss of heterozygoisty suggests tumor suppressor gene responsible for primary hepatocellular carcinoma. Proc Natl Acad Sci U S A 1989; 86: 88528856.
  • 14
    Piao Z, Park C, Park J-H, Kim H. Allelotype analysis of hepatocellular carcinoma. Int J Cancer 1998; 75: 2933.
  • 15
    Yumoto Y, Hanafusa T, Hada H, Morita T, Oocushi S, Shinji N, Mitani T, et al. Loss of heterozygosity and analysis of mutation of p53 in hepatocellular carcinoma. J Gastroenterol Hepatol 1995; 10: 179185.
  • 16
    Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
  • 17
    Seizinger BR, Kiinger HP, Junien C, Nakamura Y, Le Beau M, Cavanee W, Emanuel B, et al. Report of the committee on chromosome and gene loss in human neoplasia. Cytogenet Cell Genet 1991; 58: 10801096.
  • 18
    Rashid A, Wang J-S, Qian G-S, Lu B-X, Hamilton SR, Groopman JD. Genetic alterations in hepatocellular carcinomas: association between loss of chromosome 4q and p53 gene mutations. Br J Cancer 1999; 80: 5966.
  • 19
    De Souza AT, Hankins GR, Washingon MK, Fine RL, Orton TC, Jirtle RL. Frequent loss of heterozygosity on 6q at the emannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene 1995; 10: 17251729.
  • 20
    Suzuki K, Hirooka Y, Tsujitani S, Yamane Y, Ikeguchi M, Kaibara N. Relationship between loss of heterozygosity at microsatellite loci and computerized nuclear morphometry in hepatocellular carcinoma. Anticancer Res 2000; 20: 12571262.
  • 21
    Biden K, Young J, Buttenshaw R, Searle J, Cooksley G, Xu D-B, Leggett B. Frequency of mutation and deletion of the tumor suppressor gene CDKN2A (MTS1/p16) in hepatocellular carcinoma from an Australian population. Hepatology 1997; 25: 593597.
  • 22
    Kuroki T, Fujiwara Y, Nakamori S, Imaoka S, Kanematsu T, Nakamura Y. Evidence for the presence of two tumor suppressor genes for hepatocellular carcinoma on chromosome 13q. Br J Cancer 1995; 72: 383285.
  • 23
    Gramantieri L, Trere D, Pession A, Piscaglia F, Masi L, Gaiani S, Mazziotti A, et al. Allelic imbalance on 16q in small, unifocal hepatocellular carcinoma: correlation with HBV and HCV infections and cellular proliferation rate. Dig Dis Sci 2000; 45: 306311.
  • 24
    Boige V, Larent-Puig P, Fouchet P, Flejou JF, Monges G, Bedossa P, Biolac-Sage P, et al. Concerted nonsymtenic allelic losses in hyperploid hepatocellular carcinoma as determined by a high-resolution allelotype. Cancer Res 1997; 57: 19861990.
  • 25
    Hammond C, Jeffers L, Carr BI, Simon D. Multiple genetic alterations, 4128, a new suppressor region, and potential gender differences in human hepatocellular carcinoma. Hepatology 1999; 29: 14791485.
  • 26
    Nagai H, Pineau P, Tiollais P, Buendia AM, Dejean A. Comprehensive allelotype of human hepatocellular carcinoma. Oncogene 1997; 14: 29272933.
  • 27
    Okabe H, Ikai I, Matsuo K, Satoh S, Momi H, Kamikawa T, Katsura N, et al. Comprehensive allelotype study of hepatocellular carcinoma: potential differences in pathways to hepatocellular carcinoma between hepatitis B virus-positive and -Negative tumors. Hepatology 2000; 31: 10731079.
  • 28
    Kawai H, Suda T, Aoyagi Y, Isokawa O, Mita Y, Waguri N, Kuroiwa T, et al. Quantitative evaluation of genomic instability as a possible predictor for development of hepatocellular carcinoma: comparison of loss of heterozygosity and replication error. Hepatology 2000; 31: 12461250.
  • 29
    Sheu J-C. Molecular mechanism of hepatocarcinogenesis. J Gastroenterol Hepatol 1997; 12: S309S313.
  • 30
    Fujimori M, Tokino T, Hino K, Kitagawa T, Imamura T, Okamoto E, Mitsunobu M, et al. Alleleotype study of primary hepatocellular carcinoma Cancer Res 1991; 51: 8993.
  • 31
    Sakai K, Nagahara H, Abe K, Obata H. Loss of heterozygosity on chromosome 16 in hepatocellular carcinoma. J Gastroenterol Hepatol 1992; 7: 288292.
  • 32
    Kusano N, Shiraishi K, Kubo K, Oga A, Okita K, Sasaki, K. Genetic aberrations detected by comparative genomic hybridization in hepatocellular carcinomas: their relationship to clinicopathologic features. Hepatology 1999; 29: 18581862.
  • 33
    Marchio A, Peneau P, Meddeb M, Terris B, Tiollais P, Bernheim A, Dejean A. Distinct chromosomal abnormality pattern in primary liver cancer of non-B, non-C patients. Oncogene 2000; 19: 37333738.
  • 34
    Marchio A, Meddeb M, Pineau P, Danglot G, Tiollais P, Bernheim A, Dejean A. Recurrent chromosomal abnormalities in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer 1997; 18: 5965.
  • 35
    Wong N, Lai P, Lee SW, Fan S, Pang E, Liew CT, Sheng Z, et al. Assessment of genetic changes in hepatocellular carcinoma by comparative genomic hybridization analysis: relationship to disease stage, tumor size, and cirrhosis. Am J Pathol 1999; 154: 3743.
  • 36
    Guan XY, Fang Y, Sham JST, Kwong DLW, Zhang Y, Liang Q, Li H, et al. Recurrent chromosome alternations in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer 2000; 29: 110116.
  • 37
    Tornillo J, Carafa V, Richter J, Sauter G, Mock H, Minola E, Gambacorta M, et al. Marked genetic similarities between hepatitis B virus-positive and hepatitis C virus-positive hepatocellular carcinoma. J Pathol 2000; 192: 307312.
  • 38
    Wong N, Lai P, Pang E, Fung L-F, Sheng Z, Wong V, Wang W, et al. Genomic aberrations in human hepatocellular carcinoma of differing etiologies. Clin Cancer Res 2000; 6: 400040009.
  • 39
    Chen Y-J, Yeh S-H, Chen J-T, Wu C-C, Shu M-T, Tsai S-F, Chen P-J, et al. Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma. Gastroenterology 2000; 119: 431440.
  • 40
    Balsara BR, Pei J, DeRienzo A, Simon D, Tosolini A, Lu YY, Shen F-M, et al. Human hepatocellular carcinoma is characterized by a highly consistent pattern of genomic imbalances, including frequent loss of 16q23.1–24.1. Genes Chromosomes Cancer 2001; 30: 245253.
  • 41
    Shiraishi K, Okita K, Kusano N, Harada T, Kondoh S, Okita S, Ryozawa S, et al. A comparison of DNA copy number changes detected by comparative genomic hybridization in malignancies of the liver, biliary tract and pancreas. Oncology 2001; 60: 151161.
  • 42
    Niketeghad F, Decker HJ, Caselmann WH, Lund P, Geissler F, Dienes HP, Schirmacher P. Frequent genomic imbalances suggest commonly altered tumour genes in human hepatocarcinogenesis. Br J Cancer 2001; 85: 697704.
  • 43
    Koo SH, Ihm CH, Kwon KC, Park JW, Kim JM, Kong G. Genetic alternations in hepatocellular carcinoma and intrahepatic cholangiocarcinomas. Cancer Genet Cytogenet 2001; 130: 2228.
  • 44
    Piao Z, Park C, Park J-H, Kim H. Deletion mapping of chromosome 4q in hepatocellular carcinoma. Int J Cancer 1998; 79: 356360.
  • 45
    Yeh S-H, Chen P-J, Lai M-Y, Chen D-S. Alleleic loss on chromosome 4q and 16q in hepatocellular carcinoma: assocation with elevated α-fetoprotein production. Gastroenterology 1996; 110: 184192.
  • 46
    Kuroki T, Fujiwara Y, Tsuchiya E, Nakamori S, Imaoka S, Kanematsu T, Nakamura Y. Accumulation of genetic changes during development and progression of hepatocellular carcinoma: loss of heterozygosity on chromosome arm 1 p occurs at an early stage of hepatocarcinogenesis. Genes Chromosomes Cancer 1995; 13: 163167.
  • 47
    Roncalli M, Bianchi P, Grimaldi GC, Ricci D, Laghi J, Maggioni M, Opocher E, et al. Fractional alleleic loss in non-end stage cirrhosis: correlations with hepatocellular carcinoma development during follow-up. Hepatology 2000; 31: 846850.
  • 48
    Wang HP, Rogler CE. Deletions in human chromosome arms 11p and 13q in primary hepatocellular carcinomas. Cytogenet Cell Genet 1988; 48: 7278.
  • 49
    Lin Y-W, Sheu J-C, Liu L-Y, Chen C-H, Lee H-S, Huang G-T, Wang J-T, et al. Loss of heterozygosity at chromosome 13q in hepatocellular carcinoma: identification of three independent regions. Euro J Cancer 1999; 35: 17301734.
  • 50
    Fujimoto Y, Hampton LL, Wirth PJ, Wang NJ, Xie JP, Thorgeirsson SS. Alternations of tumor suppressor genes and alleleic losses in human hepatocellular carcinomas in China. Cancer Res 1994; 54: 281285.
  • 51
    Piao Z, Kim H, Jeon BK, Lee WU, Park C. Relationship between loss of heterozygosity of tumor suppressor genes and histologic differentiation in hepatocellular carcinoma. Cancer 1997; 80: 865872.
  • 52
    Hsu H-C, Peng S-Y, Lai P-L, Sheu J-C, Chen D-S, Lin L-I, Slagle BL, et al. Allelotype and loss of heterozygosity of p53 in primary and recurrent hepatocellular carcinomas. Cancer 1994; 73: 4247.
  • 53
    Piao Z, Kim N-G, Kim H, Park C. Deletion mapping on the short arm of chromosome 8 in hepatocellular carcinoma. Cancer Lett 1999 (a); 138: 227232.
  • 54
    Liao C, Zhao M, Song H, Uchida K, Yokoyama KK, Li T. Identification of the gene for a novel liver-related putative tumor suppressor at a highfrequency loss of heterozygosity region of chromosome 8p23 in human hepatocellular carcinoma. Hepatology 2000; 32: 721727.
  • 55
    Emi M, Fujiwara Y, Ohata H, Tsuda H, Hirohashi S, Koike M, Miyaki M, et al. Allelic loss at chromosome band 8p21.3-p22 is associated with progression of hepatocellular carcinoma. Genes Chromosomes Cancer 1993; 7: 152157.
  • 56
    Fujiwara Y, Ohata H, Kuroki T, Koyama K, Tsuchiya E, Monden M, Nakamura Y. Isolation of a candidate tumor suppresor gene on chromosome 8p21.3-p22 that is homologous to an extracellular domain of the PDGF receptor beta gene. Oncogene 1995; 10: 891895.
  • 57
    Farrington SM, Cunningham C, Boyle SM, Wyllie AH, Dunlop MG. Detailed physical and deletion mapping of 8p with isolation of YAC clones from tumor suppressor loci involved in colorectal cancer. Oncogene 1996; 12: 18031808.
  • 58
    Li S-P, Wang H-Y, Li J-Q, Zhang C-Q, Feng Q-S, Huang P, Yu X-J, Huang L-X, et al. Genome-wide analyses on loss of heterozygosity in hepatocellulaar carcinoma in Southern China. J Hepatol 2001; 34: 840849.